Global Pulmonary Drug Delivery Systems Market Size study & Forecast, by Product (Dry Powder Inhaler, Metered Dose Inhaler and Nebulizers) by Application (Asthma, Chronic Obstructive Pulmonary Diseases (COPD), and Cystic Fibrosis), by Distribution Channel

Global Pulmonary Drug Delivery Systems Market Size study & Forecast, by Product (Dry Powder Inhaler, Metered Dose Inhaler and Nebulizers) by Application (Asthma, Chronic Obstructive Pulmonary Diseases (COPD), and Cystic Fibrosis), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and E-Commerce) and Regional Analysis, 2022-2029

Global Pulmonary Drug Delivery Systems Market is valued approximately USD 46613.07 million in 2021 and is anticipated to grow with a healthy growth rate of more than 6.80% over the forecast period 2022-2029. Pulmonary drug delivery systems are devices that are used to deliver medication directly to the lungs through inhalation. These devices are commonly used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Thus, the major driving factors for the Global Pulmonary Drug Delivery Systems Market are increasing prevalence of respiratory diseases, increasing healthcare expenditure and growing demand for personalized medicine. Moreover, technological advancements and government initiatives is creating lucrative growth opportunity for the market over the forecast period 2022-2029.

The US FDA has been working to encourage the development of new pulmonary drug delivery systems. In 2019, the FDA issued a guidance document for industry on the development of inhaled drug products. The document provides recommendations on the design of clinical trials, the use of in vitro testing methods, and other aspects of product development. Similarly, in 2020, the European Medicines Agency (EMA) issued a reflection paper on the development of inhalation products. The paper provides guidance to drug developers on issues such as product design, formulation, and clinical trial design. However, the high cost of Pulmonary Drug Delivery Systems stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Pulmonary Drug Delivery Systems Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is expected to hold the largest share of the pulmonary drug delivery systems market due to the high prevalence of respiratory diseases such as asthma and COPD in the region, as well as the presence of well-established healthcare infrastructure and high levels of healthcare expenditure. The Asia-Pacific region is expected to experience the fastest growth in the pulmonary drug delivery systems market, driven by factors such as increasing healthcare expenditure, rising disposable incomes, and increasing awareness of respiratory diseases. In addition, the region's large population and high burden of respiratory diseases are expected to contribute to market growth.

Major market player included in this report are:
AstraZeneca plc
Boehringer Ingelheim GmbH
GlaxoSmithKline plc
Novartis AG
Koninklijke Philips N.V.
3M company
Janssen (Johnson & Johnson)
Clement Clarke International
Briggs Healthcare
Aerogen

Recent Developments in the Market:
In 2019, AstraZeneca launched its Bevespi Aerosphere, a dual-bronchodilator inhaler, for the treatment of chronic obstructive pulmonary disease (COPD) in the US market. The company also collaborated with Breath Therapeutics in 2019 to develop inhaled therapies for patients with pulmonary disease.
In 2020, GlaxoSmithKline received FDA approval for its Nucala autoinjector for the treatment of severe asthma. The company also announced a partnership with Verona Pharma in 2020 to develop a nebulized therapy for the treatment of respiratory diseases.
Global Pulmonary Drug Delivery Systems Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Application, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Product:
Dry Powder Inhaler
Metered Dose Inhaler and Nebulizers
By Application:
Asthma
Chronic Obstructive Pulmonary Diseases (COPD)
Cystic Fibrosis
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
E-Commerce

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

AstraZeneca plc
Boehringer Ingelheim GmbH
GlaxoSmithKline plc
Novartis AG
Koninklijke Philips N.V.
3M company
Janssen (Johnson & Johnson)
Clement Clarke International
Briggs Healthcare
Aerogen

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.